In conclusion, we suggest that R3HCC1 gene polymorphism (c.919G > A, rs2272761) may be a useful predictive biomarker for severe neutropenia associated with irinotecan‐containing chemotherapy in patients with colorectal and pancreatic cancer. This evidence concerns the gene R3HCC1 and pancreatic neoplasm.